Why Myriad case could jeopardise patents on genes
Thousands of granted US patents relating to human genes may be in danger as a result of the Supreme Court’s decision to review the Myriad case
The case, The Association for Molecular Pathology v Myriad Genetics, involves Myriad’s patent claims to the isolated DNA of the BRCA 1 and BRCA 2 genes, which can help doctors assess a woman’s risk of breast cancer and ovarian cancer....
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.